 |
busulfan |
|---|---|
| Trade Name | Partaject |
| Orphan Indication | Preparative therapy for pediatric patients undergoing bone marrow transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2002-11-25 00:00:00 |
| Sponsor | SuperGen, Inc.;4140 Dublin Blvd., Suite 200;Dublin, California, 94568 |
